



# zymeworks

## Zymeworks Announces Participation in Upcoming Investor Conferences

August 1, 2022

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Aug. 1, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

- **Citi's 17<sup>th</sup> Annual BioPharma Conference.** Zymeworks will participate in one-on-one meetings and management will participate in a fireside chat on September 7<sup>th</sup> in Boston, MA.
- **2022 Wells Fargo Healthcare Conference.** Zymeworks will participate in one-on-one meetings and management will participate in a fireside chat on September 8<sup>th</sup> in Boston, MA.
- **Morgan Stanley 20<sup>th</sup> Annual Global Healthcare Conference.** Zymeworks will participate in one-on-one meetings on September 13<sup>th</sup> and 14<sup>th</sup> in New York, NY.
- **H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference.** Zymeworks will virtually participate in one-on-one meetings on September 13<sup>th</sup> and 14<sup>th</sup> and will make available a pre-recorded presentation on September 12<sup>th</sup>.

The presentation and fireside chats will be available on Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks' second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 -targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit [www.zymeworksclinicaltrials.com](http://www.zymeworksclinicaltrials.com). For additional information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow [@ZymeworksInc](https://twitter.com/ZymeworksInc) on Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220801005087/en/): <https://www.businesswire.com/news/home/20220801005087/en/>

### Investor Inquiries:

Jack Spinks  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

### Media Inquiries:

Diana Papove  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)

Source: Zymeworks Inc.